Glenmark Pharma launches Acetylcysteine injection in US; long-term positive?

Glenmark Pharma Share Price News: Mumbai-headquartered pharmaceuticals company Glenmark Pharma's shares are in the spotlight once again on Dalal Street. The company's US arm has released its injection Acetylcysteine in the American market after acquiring an abbreviated new drug application (ANDA) from Aspen Pharma USA. An ANDA contains data that is submitted to FDA for the review and potential approval of a generic drug.

“Glenmark’s Acetylcysteine Injection, 6 gm/30 mL (200 mg/mL) Single-Dose Vials can be expected to have the same therapeutic effect as the listed drug product upon which the Agency relied as the basis of safety and effectiveness, Acetadote® Injection, 6 gm/30 mL (200 mg/mL) Single-Dose Vials of Cumberland Pharmaceuticals Inc. Glenmark acquired the ANDA for Acetylcysteine Injection, 6 gm/30 mL (200 mg/mL) Single-Dose Vials from Aspen Pharma USA Inc,” said Glenmark Pharma in a statement.

Citing IQVIATM sales data, the Indian company said that during the February 2024-January 2025 period, annual sales of approximately $15.2 million were recorded for the injection.

“We are excited to announce the acquisition and launch of Acetylcysteine Injection, 6 gm/30 mL (200 mg/mL) Single-Dose Vials. This is a great addition to our injectable portfolio in the US market as we continue to drive growth for the hospital segment,” said Marc Kikuchi, President and Business Head-North America, Glenmark Pharmaceuticals.

According to analysts at SBI Securities, the development is a long-term positive for the Indian pharmaceuticals company.

How the Glenmark Pharma stock fared on March 4

Glenmark Pharma shares reeled under selling pressure amid broad-based losses on Dalal Street.

At 9:35 am, the stock traded 1.2 per cent lower for the day at Rs 1,295.7 apiece on BSE.

Glenmark Pharma Share Price

At the current levels, the stock has rewarded investors with a 41 per cent return in the past one year, outperforming a decline of 1.8 per cent and a rise of 4.0 per cent in the Nifty 50 and Nifty Pharma indices respectively.

Glenmark Pharmaceuticals Q3 FY25 Results Summary

Last month, the drug maker reported a set of quarterly financial results that were largely in line with Street expectations.

The company registered a consolidated net profit of Rs 348 crore with revenue of Rs 3,387.6 crore for the quarter ended December 31.

Its quarterly earnings before interest, taxes, depreciation and amortisation (EBITDA) came in at Rs 600.3 crore.

According to Zee Business research, Glenmark Pharma's December-quarter net profit was estimated at Rs 350 crore, revenue at Rs 3,350 crore and EBITDA at Rs 600 crore.

Catch key stock market updates here. For all other news, visit Zeebiz.com.